AU Patent

AU2019233606B2 — Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists

Assigned to Kandy Therapeutics Ltd · Expires 2024-10-03 · 2y expired

What this patent protects

The present invention generally relates to novel pharmaceutical formulations containing 2- [3,5-Bis(trifluoromethyl)phenyl]-

USPTO Abstract

The present invention generally relates to novel pharmaceutical formulations containing 2- [3,5-Bis(trifluoromethyl)phenyl]-

Drugs covered by this patent

elinzanetant (ELINZANETANT)

Patent Metadata

Patent number: AU2019233606B2
Jurisdiction: AU
Classification: —
Expires: 2024-10-03
Drug substance claim: No
Drug product claim: No
Assignee: Kandy Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.